Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zachary Franklin Zimmerman"'
Autor:
Lynley V. Marshall, Brenda J. Weigel, G. Lesa, Joe McDonough, Malcolm A. Smith, Gudrun Schleiermacher, Nick Bird, Franca Ligas, Elly Barry, Yael P. Mosse, D Valteau, Eric J. Lowe, Nicholas Richardson, François Doz, Meredith S. Irwin, Zachary Franklin Zimmerman, Toby Trahair, Koen Norga, Sonia Singh, Martha Donoghue, Steven G. DuBois, Susan L. Weiner, Michela Casanova, Giovanni Selvaggi, Andrew D.J. Pearson, Dominik Karres, Yousif Matloub, Keith D. Wilner, Teresa de Rojas, Nicole Scobie, Rajkumar Venkatramani, Gilles Vassal, H.N. Caron, Amar Gajjar, Amy Barone, Patricia Blanc, Margret Merino, Diana Bradford, Gregory H. Reaman, Willi Woessmann, Elizabeth Fox, Vickie Buenger, Julie Park, Karsten Nysom
Publikováno v:
European Journal of Cancer. 157:198-213
The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums focused on anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. ALK is an important oncogene and target in several paediatric tumours (anaplastic large c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20a27456377fec5606ed5dc5201b2b93
https://doi.org/10.1016/j.ejca.2021.08.022
https://doi.org/10.1016/j.ejca.2021.08.022
Autor:
Shiraj Sen, Lyudmilla Bazhenova, Le, X.[Le, X.], Je-Ho Lee, Mariano Ponz-Sarvise, Xuan, D.[Xuan, D.], Zachary Franklin Zimmerman, Rebecca S. Heist, David S. Hong, Junming, Z.[Junming, Z.], Byoung Chul Cho
Publikováno v:
European Journal of Cancer. 138:S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21ee74667221ae76d64779f65a9a407b
https://doi.org/10.1016/s0959-8049(20)31074-1
https://doi.org/10.1016/s0959-8049(20)31074-1
Autor:
Xin Zhang, Vivek Subbiah, Evan Rogers, Dayong Zhai, Laura Rodon, Brion W. Murray, Wei Deng, Dong Lee, Armin Graber, Ung Jane, Alexander Drilon, Zachary Franklin Zimmerman
Publikováno v:
Journal of Clinical Oncology. 38:3616-3616
3616 Background: RET fusions/mutations drive oncogenesis in lung and thyroid cancers, and several other malignancies. Selective RET inhibitors (selpercatinib/pralsetinib) are active in patients with these cancers; unfortunately, resistance often occu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98d9493b027197431e567002c73b66c8
https://doi.org/10.1200/jco.2020.38.15_suppl.3616
https://doi.org/10.1200/jco.2020.38.15_suppl.3616
Autor:
Shiraj Sen, Zachary Franklin Zimmerman, Haeseong Park, Rebecca S. Heist, Shirish M. Gadgeel, David S. Hong, Lyudmila Bazhenova
Publikováno v:
Journal of Clinical Oncology. 38:TPS3663-TPS3663
TPS3663 Background: Alterations in the MET gene, including amplifications, chromosomal translocations, and activating mutations (kinase domain [KD] or exon 14 [Δex14]), occur across various tumors and may function as oncogenic drivers. SRC family ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::010dfbc9b1d2b60cf5672d470ec7f392
https://doi.org/10.1200/jco.2020.38.15_suppl.tps3663
https://doi.org/10.1200/jco.2020.38.15_suppl.tps3663
Autor:
T. Hu, H. Zhuang, Zachary Franklin Zimmerman, Dong Lee, Vivek Subbiah, Armin Graber, Jeffrey P. Whitten, J. Jean Cui, Ung Jane, Y. Lu, Dayong Zhai, Wei Deng, J. Liu, R. Xin, Zhongdong Huang, Han Zhang, Evan Rogers, Xin Zhang, A. Drilon
Publikováno v:
Annals of Oncology. 30:v190-v191
Background Oncogenic activation of the receptor tyrosine kinase (RTK) RET via point mutation or genomic rearrangement has been identified in multiple cancers, including medullary and papillary thyroid cancers, and non-small cell lung cancer (NSCLC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78349b3aff4f6a1f3c474eb428279d4d
https://doi.org/10.1093/annonc/mdz244.068
https://doi.org/10.1093/annonc/mdz244.068
Autor:
Amandeep Godara, John A. Thompson, Sylvia Lee, Zachary Franklin Zimmerman, Amila Patel, Anna Brown, Kim Margolin, Jason K. Rockhill, Jon Smith, Barry E. Storer, Scott S. Tykodi, Shailender Bhatia
Publikováno v:
Journal of Clinical Oncology. 31:e20048-e20048
e20048 Background: Ipi (anti-CTLA4 antibody) is associated with improved survival and durable responses in a subset of melanoma pts. However, the optimal dose and schedule remain unclear and an unmet need to identify predictors of clinical benefit ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d2d413bf52bd77fef25eb3a34bffc9f
https://doi.org/10.1200/jco.2013.31.15_suppl.e20048
https://doi.org/10.1200/jco.2013.31.15_suppl.e20048